A Phase Ib/II, open-label, multicenter, randomized clinical trial to evaluate atezolizumab in combination with PEGPH20 in the treatment metastatic pancreatic ductal adenocarcinoma.

Trial Profile

A Phase Ib/II, open-label, multicenter, randomized clinical trial to evaluate atezolizumab in combination with PEGPH20 in the treatment metastatic pancreatic ductal adenocarcinoma.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Hyaluronidase (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 13 Jul 2017 Status changed from planning to recruiting, according to a Halozyme Therapeutics media release.
    • 28 Nov 2016 New trial record
    • 10 Nov 2016 According to Halozyme Therapeutics media release, this study is expected in the beginning in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top